|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL and Miller KD: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL and Miller KD: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tehrani SS, Karimian A, Parsian H,
Majidinia M and Yousefi B: Multiple functions of long non-coding
RNAs in oxidative stress, DNA damage response and cancer
progression. J Cell Biochem. 119:223–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramnarine VR, Kobelev M, Gibb EA, Nouri M,
Lin D, Wang Y, Buttyan R, Davicioni E, Zoubeidi A and Collins CC:
The evolution of long noncoding RNA acceptance in prostate cancer
initiation, progression, and its clinical utility in disease
management. Eu Urol. 76:546–559. 2019. View Article : Google Scholar
|
|
9
|
Fatima R, Akhade VS, Pal D and Rao SM:
Long noncoding RNAs in development and cancer: Potential biomarkers
and therapeutic targets. Mol Cell Ther. 3:52015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu P, Cai J, Chen Q, Han B, Meng X, Li Y,
Li Z, Wang R, Lin L, Duan C, et al: Lnc-TALC promotes
O6-methylguanine-DNA methyltransferase expression via
regulating the c-Met pathway by competitively binding with
miR-20b-3p. Nat Commun. 10:20452019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu XS, Wang F, Li HF, Hu YP, Jiang L,
Zhang F, Li ML, Wang XA, Jin YP, Zhang YJ, et al: LncRNA-PAGBC acts
as a microRNA sponge and promotes gallbladder tumorigenesis. EMBO
Rep. 18:1837–1853. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peng W, He D, Shan B, Wang J, Shi W, Zhao
W, Peng Z, Luo Q, Duan M, Li B, et al: LINC81507 act as a competing
endogenous RNA of miR-199b-5p to facilitate NSCLC proliferation and
metastasis via regulating the CAV1/STAT3 pathway. Cell Death Dis.
10:5332019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang G, He X, Ren C, Lin J and Wang Q:
Long noncoding RNA PCA3 regulates prostate cancer through sponging
miR-218-5p and modulating high mobility group box 1. J Cell
Physiol. 234:13097–13109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu X, Xiao Y, Zhou Y, Zhou Z and Yan W:
LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of
prostate cancer by sequestering miR-3184-5p to upregulate FOXP4.
Cell Death Dis. 10:4722019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng G, Song Z, Liu Y, Xiao H, Ruan H,
Cao Q, Wang K, Xiao W, Xiong Z, Liu D, et al: Long noncoding RNA
SNHG12 indicates the prognosis of prostate cancer and accelerates
tumorigenesis via sponging miR-133b. J Cell Physiol. 235:1235–1246.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Zhang R, Zhao N, Zhang Q, Yan Z,
Chang Z, Wei Y, Wu C, Xu J and Xu Y: A comparative analysis reveals
the dosage sensitivity and regulatory patterns of lncRNA in
prostate cancer. Mol Biosyst. 12:3176–3185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Jiang M, Liu Q, Han Z, Zhao Y and
Ji S: miR-145-5p inhibits the proliferation and migration of
bladder cancer cells by targeting TAGLN2. Oncol Lett. 16:6355–6360.
2018.PubMed/NCBI
|
|
21
|
Chen Y and Wang X: miRDB: An online
database for prediction of functional microRNA targets. Nucleic
Acids Res. 48:D127–D131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar
|
|
23
|
Paraskevopoulou MD, Vlachos IS, Karagkouni
D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P,
Floros E, Dalamagas T and Hatzigeorgiou AG: DIANA-LncBase v2:
Indexing microRNA targets on non-coding transcripts. Nucleic Acids
Res. 44:D231–D238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aiello NM and Kang Y: Context-dependent
EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Golden RJ, Chen B, Li T, Braun J,
Manjunath H, Chen X, Wu J, Schmid V, Chang TC, Kopp F, et al: An
Argonaute phosphorylation cycle promotes microRNA-mediated
silencing. Nature. 542:197–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakurai K, Reon BJ, Anaya J and Dutta A:
The lncRNA DRAIC/PCAT29 locus constitutes a tumor-suppressive
nexus. Mol Cancer Res. 13:828–838. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cochetti G, Poli G, Guelfi G, Boni A,
Egidi MG and Mearini E: Different levels of serum microRNAs in
prostate cancer and benign prostatic hyperplasia: Evaluation of
potential diagnostic and prognostic role. OncoTargets Ther.
9:7545–7553. 2016. View Article : Google Scholar
|
|
28
|
Guelfi G, Cochetti G, Stefanetti V,
Zampini D, Diverio S, Boni A and Mearini E: Next generation
sequencing of urine exfoliated cells: An approach of prostate
cancer microRNAs research. Sci Rep. 8:71112018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Egidi MG, Cochetti G, Serva MR, Guelfi G,
Zampini D, Mechelli L and Mearini E: Circulating microRNAs and
kallikreins before and after radical prostatectomy: Are they really
prostate cancer markers? Biomed Res Int. 2013:2417802013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu R and Lu Z: Long non-coding RNA HCP5
promotes prostate cancer cell proliferation by acting as the sponge
of miR-4656 to modulate CEMIP expression. Oncol Rep. 43:328–336.
2020.PubMed/NCBI
|
|
31
|
Jin C, Wang A, Liu L, Wang G, Li G and Han
Z: miR-145-5p inhibits tumor occurrence and metastasis through the
NF-κB signaling pathway by targeting TLR4 in malignant melanoma. J
Cell Biochem. Jan 30–2019.(Epub ahead of print). View Article : Google Scholar
|
|
32
|
Lu Q, Shan S, Li Y, Zhu D, Jin W and Ren
T: Long noncoding RNA SNHG1 promotes non-small cell lung cancer
progression by up-regulating MTDH via sponging miR-145-5p. FASEB J.
32:3957–3967. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun M, Zhao W, Chen Z, Li M, Li S, Wu B
and Bu R: Circular RNA CEP128 promotes bladder cancer progression
by regulating Mir-145-5p/Myd88 via MAPK signaling pathway. Int J
Cancer. 145:2170–2181. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xue D, Lu H, Xu HY, Zhou CX and He XZ:
Long noncoding RNA MALAT1 enhances the docetaxel resistance of
prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
J Cell Mol Med. 22:3223–3237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu W, Chang J, Du X and Hou J: Long
non-coding RNA PCAT-1 contributes to tumorigenesis by regulating
FSCN1 via miR-145-5p in prostate cancer. Biomed Pharmacother.
95:1112–1118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Egidi MG and Cochetti G: Stability
assessment of candidate reference genes in urine sediment of
prostate cancer patients for miRNA applications. Dis Markers.
2015:9735972015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cochetti G, Rossi de Vermandois JA, Maulà
V, Giulietti M, Cecati M, Del Zingaro M, Cagnani R, Suvieri C,
Paladini A and Mearini E: Role of miRNAs in prostate cancer: Do we
really know everything? Urol Oncol. 38:623–635. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saijo M, Sakai Y, Kishino T, Niikawa N,
Matsuura Y, Morino K, Tamai K and Taya Y: Molecular cloning of a
human protein that binds to the retinoblastoma protein and
chromosomal mapping. Genomics. 27:511–519. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gallie BL, Campbell C, Devlin H, Duckett A
and Squire JA: Developmental basis of retinal-specific induction of
cancer by RB mutation. Cancer Res. 59 (7 Suppl):1731S–1735S.
1999.PubMed/NCBI
|
|
40
|
Zhou H, Bao J, Zhu X, Dai G, Jiang X, Jiao
X, Sheng H, Huang J and Yu H: Retinoblastoma binding protein 5
correlates with the progression in hepatocellular carcinoma. BioMed
Res Int. 2018:10734322018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xia B, Joubert A, Groves B, Vo K, Ashraf
D, Djavaherian D, Awe J, Xiong Y, Cherfils J and Ma D: Modulation
of cell adhesion and migration by the histone methyltransferase
subunit mDpy-30 and its interacting proteins. PLoS One.
5:e117712010. View Article : Google Scholar : PubMed/NCBI
|
